

SANOFI-AVENTIS  
Form 6-K  
January 28, 2008

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 6-K**  
**REPORT OF FOREIGN PRIVATE ISSUER**  
**PURSUANT TO RULE 13a-16 OR 15d-16**  
**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of January 2008

Commission File Number: 001-31368

**SANOFI-AVENTIS**

(Translation of registrant's name into English)

174, avenue de France, 75013 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

In January 2008, sanofi-aventis issued the press releases attached hereto as Exhibits 99.1 and 99.2, which are incorporated herein by reference.

**Exhibit List**

<u>Exhibit No.</u>	<u>Description</u>
Exhibit 99.1	Press release dated January 3, 2008: Sanofi Pasteur enters Agreement with Crucell for next-generation Biologicals against Rabies.
Exhibit 99.2	Press release dated January 28, 2008: Clexane <sup>®</sup> /Lovenox <sup>®</sup> approved in Japan.



**Exhibit Index**

<u>Exhibit No.</u>	<u>Description</u>
Exhibit 99.1	Press release dated January 3, 2008: Sanofi Pasteur enters Agreement with Crucell for next-generation Biologicals against Rabies.
Exhibit 99.2	Press release dated January 28, 2008: Clexane <sup>®</sup> /Lovenox <sup>®</sup> approved in Japan.